Breast cancer pathogenesis is known to be propagated by the differential expression of a 11 group of proteins called the Kinesin Superfamily (KIFs), which are instrumental in the 12 intracellular transport of chromosomes along microtubules during mitosis. During mitosis, 13
MB-231]) in both cell lines, but had no effect on adhesion or proliferation, suggesting that 28 KIF21A plays an important role in the early stages of breast cancer metastasis. Unexpectedly 29 however, KIF21A was shown to negatively correlate with various pro-malignant 30 clinicopathological parameters, including tumour size and histological grade, and high 31 KIF21A expression predicted better breast cancer survival (hazard ratio = 0.45), suggesting 32 that KIF21A is a tumour suppressor. The conflicting outcomes of in vitro and in vivo data 33 may be due to the possible multi-functionality of KIF21A or study limitations, and means no 34 definitive conclusions can be drawn about the role of KIF21A in breast cancer. This warrants 35 further investigation, which may prove pivotal to the development of novel chemotherapeutic 36 strategies to mediate KIF21A's function and enhance prognostic outcomes. 37
INTRODUCTION 39
Breast cancer is the most frequently diagnosed cancer among women [1] , and its metastasis 40 often leads to death in patients. Breast cancer pathogenesis is known to be affected by the 41 differential expression of a group of proteins called the kinesin superfamily (KIF) [2] . 42
Kinesins were first isolated from squid tissue and identified as molecular motors for axonal 43 transport that are ubiquitous in all eukaryotes [3] . In total, 45 kinesins have been identified in 44 humans and other mammals [4, 5] . They are sorted into 14 subfamilies based on structural 45 dependent motion potential, allowing movement along microtubules through coupling energy 48 from ATP hydrolysis to force production [6] . 49 The role of kinesins has since been specified in the transport of vesicles and organelles within 50 cells, and chromosomes during mitosis and meiosis. During mitosis, kinesins are strictly 51 regulated through temporal synthesis so that they are only present when needed [7] . 52
However, misregulation of kinesins during the cell cycle may contribute to uncontrolled cell 53 growth, highlighting their involvement in tumorigenesis. For example, either the depletion or 54 overexpression of some mitotic kinesins can lead to unbalanced movement of chromosomes 55 along microtubules during mitosis [8] . This causes a cascade of excessive spindle separation, 56 premature sister chromatid separation, overshooting before anaphase, and finally unequal 57 distribution of DNA and aneuploidy [9] [10] [11] . The aneuploid daughter cells may display 58 cancerous behaviour, including increased metastatic behaviour [12] . 59
Furthermore, Some KIFs have recently been associated with poor prognosis [13] [14] [15] [16] [17] [18] and 60 chemotherapeutic drug resistance [19] [20] [21] in breast cancer patients and cell lines, respectively. 61
Such an involvement in mitotic deregulation, clinical outcomes and chemotherapeutic 62 resistance in breast cancer highlights the importance of understanding the molecular 63 mechanisms underlying the behaviour of KIFs. 64
One particular KIF, KIF21A, was recently found to promote lysosomal stability and the 65 survival of human breast cancer cells in vitro [22] . However, how KIF21A distinctly affects 66 other malignant phenotypes and prognostic outcomes in breast cancer is currently unknown. 67
This study therefore aimed to (1) identify whether KIF21A is overexpressed in breast cancer 68 tissue; (2) understand the functional behaviour of KIF21A in breast cancer cell lines and (3) 69 medium on the outside of the inserts was 600 μL fresh culture medium, supplemented with 169 30% FBS. The plate was left in an incubator for 24 hours at 37 °C. Invaded cells were then 170 fixed, stained, imaged and quantified in an identical manner to the migration assay. 171
Serum-Starved Proliferation Assay 173
Proliferation assays were performed using the CellTiter 96 Aqueous One Solution Cell 174
Proliferation Assay (Promega, Fitchburg, WI, USA). To begin, cells were serum-starved 175 overnight prior to seeding, i.e. sub-cultured in fresh medium in a 25-cm 2 flask without FBS. 176 siRNA transfection was performed as per section 4.2. 72 hours post-transfection, culture 177 medium was removed and replaced with 1.8 mL fresh medium (10% FBS) with 300 μL MTS 178 reagent. Samples were incubated at 37 °C for 1 hour prior to measuring absorbance values 179 once every hour for 4 hours. Formazan absorbance was detected at 490 nm by a GENios 180
Plate Reader (Tecan, Austria). 181
Cell Adhesion Assay 182
96-well plates were coated overnight with either 50 μL collagen I (Corning) or 50 μL 183 fibronectin (BD Biosciences), both at concentrations of 20 μg/mL. Collagen I and fibronectin 184 were then removed and the wells were washed twice with 1X PBS. 100 μL 1% BSA (Sigma-185 Aldrich) was then added to the same wells for 1 hour at room temperature for blocking. BSA 186 was then removed and the wells were washed twice with 1X PBS. siRNA transfection was 187 performed as per section 4.2. 48 hours post-transfection, cells were harvested, resuspended 188 with fresh medium and seeded into the wells at a density of 1 x 10 4 cells for collagen I and 3 189 and finally washed in distilled water. The slides were then washed in 1X Tris-buffered saline 206 (TBS) (Bio-Rad), incubated with 3% hydrogen peroxide for 30 minutes to block endogenous 207 peroxidase activity, and washed in 1X TBS with 1% Triton X-100 (TBS-TX) (Bio-Rad) 208 thrice. Antigen retrieval was performed by boiling the slides at 100 °C for 20 minutes in a 209 500 mL solution containing 0.1 M sodium citrate, 0.1 M citric acid and distilled water. After 210 cooling to room temperature, the slides were washed in 1X TBS-TX three times. They were 211 then blocked for 1 hour using 1:100 dilution goat serum (Dako, Agilent Technologies, 212 Denmark) at room temperature, followed by KIF21A primary antibody (1:100 dilution; Table  213 2) incubation overnight at 4 °C. The next day, the slides were washed in 1X TBS-TX, then 214 incubated with undiluted horseradish peroxidase (HRP) conjugated secondary antibodies 215 (polyclonal goat anti-rabbit immunoglobulins, Dako, catalogue no. K4010) for 1 hour at 216 room temperature, and washed again in 1X TBS-TX. To visualise the staining, the slides 217 were incubated with 3,3'-Diaminobenzidine (DAB) (Thermo Fisher Scientific) for 30 218 minutes, followed by counter-staining in filtered concentrated Shandon Harris haematoxylin 219 (Thermo Fisher Scientific) for 30 seconds. The slides were finally dehydrated in a graded 220 series of ethanol and washed twice in Clearene, followed by fixing in Permount (Thermo 221
Fisher Scientific). 222 223
The fixed TMA slides were scanned and their staining intensities assessed using Philips 224
Image Management System software (Philips, Amsterdam, Netherlands). KIF21A immuno-225 positivity was scored independently by one individual followed by confirmation by a trained 226 pathologist. The scoring criteria was based on KIF21A staining intensities with '0' = no 227 staining, '1+' = weak staining intensity, '2+' = moderate staining intensity, and '3+' = strong 228 staining intensity. Weighted average intensity (WAI) was then calculated, which is the 229 average intensity of each stained cell 230 231
Statistical Analysis 232
For qRT-PCR and all functional assays, Prism 5 (GraphPad Software, La Jolla, CA, USA) 233 was used to conduct statistical analysis. One-way ANOVAs were utilised to detect significant 234 (Figures 1 C,D) . 262
Transwell Migration Assay 263
KIF21A silencing in MCF-7 resulted in a 42.8% (p < 0.01) and 39.8% (p < 0.01) decrease in 264 the average number of migrated cells for siKIF21A-1 and siKIF21A-2 groups, respectively, 265 compared to the negative control (Figures 2A,B) . KIF21A silencing in MDA-MB-231 266 reduced cell migration by 69.7% (p < 0.0001) and 64.6% (p < 0.001) for siKIF21A-1 and 267 siKIF21A-2, respectively, compared to the negative control ( Figures 2C,D) . 268
Matrigel Invasion Assay 269
KIF21A silencing in MCF-7 resulted in a 42.5% (p < 0.001) and 72.5% (p < 0.0001) decrease 270 in the average number of invaded cells for siKIF21A-1 and siKIF21A-2 groups, respectively, 271 compared to the negative control ( Figures 3A,B) . KIF21A silencing in MDA-MB-231 272 reduced cell invasion by 42.5% (p < 0.05) and 41.0% (p < 0.05) for siKIF21A-1 and 273 siKIF21A-2, respectively, compared to the negative control ( Figures 3C,D) . 274
Cell Proliferation Assay 275
Analysis of cell proliferation showed no significant differences in cell proliferation between 276 the negative and KIF21A-silenced groups for both MCF- 
Breast IDC Tissues 295
Cut-off values above and below the mean WAI (1.0) were determined as "high" and "low" 296 KIF21A expression, respectively. High KIF21A expression correlated with tumour size 297 below 20 mm (p < 0.05), and progressively lower histological grades (p < 0.01; Table 5 ). No 298 significant correlations were observed between KIF21A and other parameters. 299
Univariate (Kaplan-Meier) analysis of survival and KIF21A expression 300
The three timelines investigated were overall survival (OS), survival after recurrence (SAR), 301 and disease-free survival (DFS). Survival data is cause-specific and was available for all 302 cases, with a follow-up period ranging from 0 months to 156 months. It should be noted that 303 no patients survived after breast cancer recurrence for the entire follow-up period (Table 6) . 304 Surprisingly, Kaplan-Meier analysis showed patients with high nuclear KIF21A expression 305 were more likely to have better overall survival (p < 0.05; Figure 6A ) and survival after 306 recurrence (p < 0.05; Figure 6B ). However, nuclear KIF21A expression was not identified as 307 a significant predictor of breast cancer recurrence, as measured by DFS ( Figure 6C) . 308
Multivariate (Cox proportional hazards regression) analysis of survival and KIF21A 309 expression 310
Variables that achieved statistical significance in univariate analyses (p < 0.05) were 311 subsequently entered into a multivariate analysis using Cox proportional hazards model via 312 the backward stepwise regression method (Model A; Table 7 ). In addition, to examine the 313 prognostic value of KIF21A in greater detail, the analysis included a multivariate Cox 314 proportional hazards model that included all clinicopathological parameters via the enter 315 method (Model B; Table 7 ). This included patients' age, race, tumour size, histological grade, 316 lymph node involvement, lymphovascular invasion, and ER, PR and HER2 statuses. 317
However, only those which showed statistical significance (p < 0.05) are shown in Table 7 . 318
Model A showed KIF21A acts independently to predict SAR (p < 0.05), but significantly 319 correlates with tumour size in predicting OS (p < 0.05). Model B predicted KIF21A as an 320 independent prognostic factor for both OS (p < 0.05) and SAR (p < 0.05). However, both 321 models showed KIF21A expression was not a prognostic factor for recurrence, as measured 322 by DFS. 323
DISCUSSION 325

KIF21A Mediates Breast Cancer Metastasis In Vitro 326
This study identifies KIF21A as a protein whose depletion consistently caused a statistically 327 and biologically significant reduction in breast cancer cell migration and invasion in vitro 328 (Figures 2 and 3 ). To our knowledge, this is the first study to identify the role of KIF21A in 329 cancer cell metastasis -an important finding in the assessment of KIF21A as a potential 330 therapeutic target. Invasion of malignant cells into the surrounding ECM and migration of 331 invaded cells towards the bloodstream are pivotal early steps in metastasis, suggesting that 332 KIF21A is an important mediator of early carcinogenesis. The observed migratory influence 333 of KIF21A was enhanced in MDA-MB-231 cells, which are known to be highly metastatic, 334 while higher silencing efficiency using siKIF21A-2 in MCF-7 intensified the reduction in 335 migration. Furthermore, although a more optimal silencing efficiency would be preferred to 336 observe the full effects of KIF21A knockdown, there was still a significant reduction in both 337 invasion and migration. Whether complete knockdown would have accentuated this 338 observation remains unknown. Nonetheless, these cumulative findings suggest that KIF21A 339 may be a key component of breast cancer cell migratory and invasive pathways. This could 340 be explained by its interaction with other molecules and their known mechanisms (see 341
Section 4.3 below). 342
However, these observations surprisingly contradicted the in vivo findings of KIF21A 343 expression in human breast cancer tissue (discussed in-detail in Section 4.2), meaning that 344 KIF21A's role in cancer metastasis is largely inconclusive. Despite this, in vitro functional 345 assays do serve an important purpose. Although they are only representative of complex in 346 vivo conditions, they provide a critical understanding about the influence of genes on distinct 347 metastatic components. In this case, KIF21A was shown to influence the distinct metastatic 348 components of migration and invasion -a phenomenon supported by studies of other kinesin 349 family members. KIF3A and KIF3B, for example, have been shown to interact in a complex 350 that transports proteins essential for cancer cell migration [23] , while KIF11 has been found 351 to respond to directional cues during chemotaxis to govern the direction of MDA-MB-231 352 cell migration [24] . Other studies identify KIF14 [25] , KIF2A [26] , and KIF18A [27] as 353 mediators of breast cancer migration in vitro via a range of pathways. Given the discrepant 354 results of the current study, migration and invasion assays should be extended to in vivo 355 models to elucidate KIF21A's precise role in these processes. 356
Following migration, cancer cells must adhere to the ECM of a new site where they can then 357 rapidly proliferate. This study investigated the role of KIF21A in this process. KIF21A 358 knockdown by 40-70% did not induce any changes in cell proliferation for both breast cancer 359 cell lines (Figure 4) , and thus KIF21A is not implicated as a player in breast cell 360 proliferation. Although it is difficult to identify studies reporting similarly negative results for 361 other kinesin family members, the present study shows KIF21A varies from previous reports 362 of KIFs acting as key mediators of proliferation in breast cancer [26, 28] . 363 KIF21A was also tested for cell adhesion to collagen I and fibronectin fibers -both protein 364 components of the ECM -yet no changes were observed following silencing in MCF-7 for 365 both fibers, and in MDA-MB-231 for collagen I fibers (Figure 4 
investigate the functional role of KIF21A in breast cancer cell adhesion, which could be done 371 via overexpression studies and other adhesion assays involving laminin, gelatin and collagen 372 II fibers. More broadly, there is no particular commonality in the adhesive capabilities of 373 other kinesins, with many being shown to either positively or negatively regulate adhesion in 374 various cell lines [25, 29, 30] . Further studies in KIF21A are therefore encouraged. 375
Disparity Between In Vitro and In Vivo Results 376
The present study suggested KIF21A exerts oncogenic activity in vitro, which resonates with 377 our hypothesis and previous studies that show KIF21A facilitates the survival of breast 378 cancer cell lines [22] . However, conflicting results were obtained in vivo. 
KIF21A Signaling Pathways Leading to Cell Migration and Invasion 408
Although few studies have investigated KIF21A beyond its role in congenital fibrosis of the 409 extraocular muscles type-1 (CFEOM1), evidence suggests it may interact with other genes 410 involved in cell migration. KIF21A binds to brefeldin A (BFA)-inhibited guanine nucleotide-411 exchange factor (BIG1) [35] to maintain the organisation of the Golgi apparatus [36] , and 412 also transports KN motif and ankyrin repeat domains 1 (KANK1), influencing its membrane 413 localisation [37] . Subsequent exploration revealed that both BIG1 and KANK1 co-414 immunoprecipitated with KIF21A and each other, such that they may act as a scaffold in 415 KIF21A-powered intracellular transport [38] . The interaction between all three molecules 416 was shown to affect cell migration; a phenomenon explained by their combined effects on 417 cell polarity. Generation and maintenance of cell polarity is essential for directional migration 418 and results from asymmetric membrane traffic achieved by intracellular transport and the 419 delivery of extra membrane to the cell's leading edge [39, 40] . KIF21A is theorised to act via 420
BIG1 and KANK1 to position the Golgi and microtubule-organising center (MTOC) 421
structures anterior to the nucleus, resulting in a polarity shift that induces front-end-directed 422 cell migration [38] . This interaction would explain the observations seen in breast cancer cell 423 migration in the present study. In support of this theory, previous studies show polarisation of 424
Golgi and MTOC structures to be explicitly disturbed by KANK1 or BIG1 siRNA treatment 425 [38] . However, further investigation is required to identify additional players in 426 KIF21A/BIG1/KANK1 functional interactions and to elucidate the detailed molecular 427 mechanisms that alter cell polarity to influence directional migration. 428 429
KIF21A in Breast Cancer Tissues 430
Although our in vitro data strongly supported a tumorigenic role for KIF21A in breast cancer, 431 IHC in breast cancer tissue microarrays was contrary to our hypothesis and showed KIF21A 432 associated with anti-malignant phenotypes and a better prognosis. Both analyses suggest 433 KIF21A is involved in breast cancer pathogenesis and prognosis, however their conflicting 434 outcomes mean the overall results of this study remain largely inconclusive. 435 Nonetheless, numerous important findings came from the IHC analysis. Firstly, there were no 436 significant differences in KIF21A expression between breast IDC samples and adjacent 437 normal tissues ( Figure 5 ). This adds to inconsistent evidence regarding the role of KIF21A in 438 breast oncogenesis, and is contradictory to previous studies in the kinesin superfamily, which 439 observe upregulation of numerous KIFs in breast cancer [13, 15, 17] . KIF21A may therefore 440 not be a useful diagnostic biomarker. 441
442
In addition, KIF21A expression was shown to negatively correlate with the pro-malignant 443 phenotypes of large tumour size (≥ 20 mm) and high histological grade (Table 5) . Large 444 tumour size and high histological grade classically predict poorer prognosis in breast cancer 445 [41] , so KIF21A may exert a tumour-suppressive role during breast carcinogenesis. However, 446 the mechanism via which it performs this role was not clear from the IHC analysis, as 447
KIF21A displayed no relationships with lymphovascular invasion, lymph node involvement, 448
or various receptors including ER, PR, and HER2. This suggests KIF21A may not regulate 449 distant metastasis to lymph nodes and blood vessels (in contradiction to the in vitro 450 observations), and it may not be involved in the mechanisms through which oestrogen, 451 progesterone and human epidermal growth factor increase breast cell proliferation. This 452 differs from previous observations of concerted KIF21A upregulation upon the introduction 453 of exogenous oestrogen in vitro [42] . One explanation for KIF21A-induced tumour 454 suppression may therefore be its role in mitosis (see Section 4.5 below). 455
456
Survival analyses were also performed, and revealed high KIF21A expression predicted 457 better OS and SAR, but had no significant associations with DFS ( Figure 6 ). KIF21A may 458 therefore act as a tumour suppressor, and may be used as a predictor of breast cancer 459 survival, but not recurrence. To identify whether KIF21A predicted survival independently of 460 other clinicopathological parameters, multivariate analyses were also performed (Table 7) . 461
Although univariate analysis suggested KIF21A co-predicted OS and SAR with tumour size 462 and histological grade, Cox proportional hazards models revealed KIF21A acted 463 independently. KIF21A may therefore be an independent prognostic biomarker for better 464 breast cancer survival. In this study cohort, lymphovascular invasion, lymph node 465 involvement, and hormonal and growth factor receptor statuses had no correlations with SAR 466 and OS -a rare finding (although some of those variables did correlate with recurrence). 467
Nonetheless, this observation adds to evidence that KIF21A functions independently of 468 lymphovascular invasive pathways, oestrogen, progesterone, and human epidermal growth 469 factor to implement its tumour-suppressive activity. 470
471
The possible role of KIF21A as a tumour suppressor and predictor of better breast cancer 472 prognosis differs from that of most other kinesin family members. KIFs 2A [43] , 2C [17] , 3C 473 [44] , and 26B [45] have all been identified as predictors of worse breast cancer prognosis. 474
Intriguingly however, a select few kinesins have been observed as tumour-suppressor genes 475 consistent with the results of the current study, albeit in other cancer types. Overexpression of 476 both KIF4 [46] and KIF14 [34] has been shown to reduce metastatic phenotypes in vitro and 477 predict better survival outcomes in human gastric carcinoma and lung adenocarcinoma, 478 respectively. In both cases, it was theorised that they carried out their tumour-suppressive 479 functions through their roles in mitosis -a phenomenon that could explain similar 480 observations in this study (see below). 481 482
Mitotic Misregulation as a Functional Explanation for KIF21A-mediated 483
Tumorigenesis 484
Errors at any point during the cell cycle can be catastrophic and in humans can lead to cancer 485 [47] . Chromosome mis-segregation during mitosis, for example, results in abnormal 486 cytokinesis and aneuploidy [48] , which is cleared in normal cells through apoptosis. 487
However, tumour cells show higher rates of aneuploidy, which is often associated with poor 488 clinical outcomes [49] [50] [51] . Interestingly, misregulation of various mitotic kinesins has been 489 shown to result in aneuploidy, because unbalanced movement of kinesins can cause excessive 490 spindle separation, premature sister chromatid detachment, overshooting before anaphase, 491
and eventually unequal distribution of DNA [8] [9] [10] [11] . The aneuploid daughter cells could, 492 theoretically, display any possible tumorigenic phenotype and a plethora of metastatic 493 characteristics, including aberrant migration and invasion. Via this mechanism, KIF21A 494 depletion could result in aneuploidy to facilitate tumour formation, which explains the in vivo 495 findings of this study. High KIF21A expression may therefore suppress carcinogenesis if 496 KIF21A is implicated in mitosis. 497
Future Work 498
The results of this study were largely inconclusive due to discrepancies between in vitro and 499 clinical data. To further elucidate KIF21A's role in breast cancer, other functional analyses 500
should therefore be performed (e.g. apoptosis and drug resistance assays) in more breast 501 cancer cell lines that have been subjected to KIF21A knockdown, overexpression and the 502 introduction of exogenous KIF21A. This would solidify knowledge about KIF21A's role in 503 breast cancer in vitro, however there still remains little physiological evidence on the role of 504 KIF21A in vivo. IHC analysis of an Asian population in this study should therefore be 505 extended to Caucasian cohorts. Furthermore, given many known KIF proteins occur in mice 506
[4], they would be an ideal animal model to knockout genes and explore physiological effects 507 in tumour xenografts. KIF21A's biological pathways are also poorly understood, and could 508 be discovered through microarray analysis of KIF21A-silenced cells. Any upstream or 509 downstream targets of KIF21A that are known breast cancer oncogenes would provoke 510 interesting follow-up studies, and have the potential to be targeted alongside KIF21A in 511 combinative therapy. 512
Because of the lack of primary data, KIF21A and many other kinesins are yet to be 513 considered therapeutic targets or prognostic predictors, despite common consensus that 514 kinesins play a vital role in breast carcinogenesis [8] . If mounting evidence supports either a 515 tumour-suppressive or oncogenic role for KIF21A in the metastatic cascade, its pathways 516 could be modulated through targeted chemotherapeutic strategies. Future studies should 517 therefore attempt to uncover the structure of KIF21A's ATP-, microtubule-and enzyme-518 binding sequences, which could lead to the development of KIF21A inhibitors and enhancers. 519
Identifying binding partners has enormous therapeutic potential, because drugs that mimic 520 those partners could bind to allosteric pockets to either promote or suppress KIF21A and its 521 effects on carcinogenesis. 522 523
Conclusions 524
In summary, this study illustrates the potential involvement of KIF21A in breast cancer 525 pathogenesis and progression. However, the conflicting outcomes of in vitro and in vivo data 526 means no definitive conclusions can be drawn about KIF21A's role in breast cancer. This 527 may be due to ethnic differences, the possible multi-functionality of KIF21A, or even study 528 limitations, and warrants further investigation into the influence of KIF21A in vivo, the 529 molecules it interacts with, and its potential as a prognostic biomarker. Such knowledge 530 could lead to the development of novel chemotherapeutic strategies to mediate its function 531 and enhance prognostic outcomes. 532 Table 1 . siRNAs used and their corresponding target sequences. Two different KIF21A siRNA sequences were tested to ensure reliability in results. Not available 44 (16.7) ER: oestrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2. recurrence (DFS timeline), while censored cases represent patients who either did not experience an event during the entire follow-up period, or who withdrew from the study during the follow-up period without experiencing an event. * Log-rank p < 0.05. 
TABLES
KIF21A 5'-AATGCTGTCAGGATG TGGGA-3' 5'-ACTCACAGTCCCAAGA GCTC-3' 186 β-ACTIN 5'- TGGCACCACACCTTCTAC AAT-3' 5'-GATAGCACAGCCTGGA TAGCA-3' 166 GAPDH 5'- GAAGGTGAAGGTCGGAG TCAACG-3' 5'-TGCCATGGGTGGAATC ATATTGG-3' 157
